23andMe Gets $300M From GlaxoSmithKline
Mountain View-based 23andMe, the provider of genetic testing services, has scored $300M in a strategic funding from GlaxoSmithKline, the two said on Tuesday. As part of the investment, the two said they are in a four-year collaboration deal to use 23andMe's genetic data, where GSK will become 23andMe's exclusive collaborator for drug target discovery programs.
posted on Wednesday, July 25, 2018 (Link to more information)
Related companies:
23andMe
Related stories:
> 23andMe Buys CureTogether
> 23andMe Gets $250M For DNA Testing Efforts
> Google Puts $3.9M In 23andMe
> 23andMe Decodes Another $50M
> 23andMe Rounds Up $200M More
silicontap.com Home